Recombinant Saccharomyces cerevisiae-CEA

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameRecombinant Saccharomyces cerevisiae-CEA
Drug Alias NameCEA重组酿酒酵母610DGI-6207
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionT lymphocytes stimulantsCarcinoembryonic antigen related cell adhesion molecule 5 modulators
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Prostatic NeoplasmsLung Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlobeimmune Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteCelgene CorpNantcell Inc
Active IndicationsN/A
Inactive IndicationsMedullary thyroid cancer (MTC)Prostatic NeoplasmsLung Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A